Marjorie Perloff, M.D.
Dr. Marjorie Perloff received an M.D. from Case Western Reserve School of Medicine and completed a medical internship and residency at Philadelphia General Hospital followed by a Hematology/Oncology Fellowship at the Albert Einstein College of Medicine. She spent several years as a faculty member at The Mt. Sinai School of Medicine where she had an oncology practice focusing on breast cancer and was an active member of the Cancer and Leukemia Group B (now Alliance for Clinical Trials in Oncology) in which she chaired and published pivotal trials in Stages II, III, and IV breast cancer as well as MER immunotherapy.
She served as a Contract Officer and Program Director in the CADRG/DCP and was responsible for the preclinical development of several agents—including fenritinide, oltipraz, DFMO, aspirin—and Naproxen in the 2012 Phase I/II Chemoprevention Consortium as well as Program Director for the PHS, WHS, and CARET grants.
Her research interests include clinical breast cancer chemoprevention, agent dosing and delivery methodologies, and preclinical agent development.